Topiramate stimulates glucose transport through AMP-activated protein kinase-mediated pathway in L6 skeletal muscle cells

Pharmacogenomics Journal

Volumn 6, Issue 5, 2006, Pages 327-332

  Ha, E ^a   Yim, S V ^a   Jung, K H ^a   Yoon, S H ^a   Zheng, L T ^a   Kim, M J ^b   Hong, S J ^c   Choe, B K ^a   Baik, H H ^a   Chung, J H ^a   Kim, J W ^a,d  

^a Kyung Hee University Hospital   (South Korea)

^b Dongduk Women's University   (South Korea)

^c CHA University   (South Korea)

^d Kyung Hee University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; TOPIRAMATE;

ANALYSIS OF VARIANCE; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; IMMUNOBLOTTING; MONOLAYER CULTURE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; WEIGHT CONTROL;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-OBESITY AGENTS; BIOLOGICAL TRANSPORT; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FRUCTOSE; GLUCOSE; HOMEOSTASIS; IMIDAZOLES; MULTIENZYME COMPLEXES; MUSCLE FIBERS; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRIDINES; RATS;

EID: 33749254291     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500366     Document Type: Article

References (34)

1. Picard F, Deshaíes Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa)Zucker rats. Obes Res 2000; 8: 656-663.
2. Hoopes SP, Reimherr FW, Hedges DW, Rosenthal NR, Kamin M, Karim R et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: Improvement in binge and purge measures. J Clin Psychiatry 2003; 64: 1335-1341.
3. Shapira NA, Goldsmith TD, McElroy S. Treatment of binge disorder with topiramate: A clinical case series. J Clin Psychiatry 2000; 61: 368-372.
4. Barbee JG. Topiramate in the treatment of severe bulimia nervosa with comorbid mood disorders: A case series. Int J Eat Disord 2003; 33: 468-472.
5. Bray GA, Hollander P, Klein S, Kushner R, Levy B, Fitchet M et al. A 6-Month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003; 11: 722-733.
6. Schmidt do Prado-Lima PA, Bacaltchuck J. Topiramate in treatment-resistant depression and binge-eating disorder. Bipolar Disord 2002; 4: 271-273.
7. Roy Chengappa KN, Levine J, Rathore D, Parepally H, Atzert R. Longterm effects of topiramate on bipolar mood instability, weight change and glycemic control: A case-series. Eur Psychiatry 2001; 16: 186-190.
8. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65(Suppl 7): 4-18.
9. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation: Evaluating the risk/benefit equation and improving the standard of care. J Clin Psychopharmacol 2004; 24(5 Suppl 1): S7-S14.
10. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis. Psychosomatics 2001; 42: 279-280.
11. Lacruz A, Baptista T, de Mendoza S, Mendoza-Guillen JM, Hernández L. Antipsychotic drug-induced obesity in rats: Correlation between leptin, insulin and body weight during sulpiride treatment. Mol Psychiatry 2000; 5: 70-76.
12. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296.
13. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs 2005; 19(Suppl 1): 1-93.
14. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002; 159: 561-566.
15. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: A systematic review. Schizophr Res 2004; 71: 195-212.
16. Ängehagen M, Ben-Menachem E, Rönnbäck L, Hansson E. Topiramate protects against glutamate- and kainite-induced neurotoxicity in primary neuronal-astroglial cultures. Epilepsy Res 2003; 54: 63-71.
17. Xi X, Han J, Zhang JZ. Stimulation of glucose transport by AMP-activated protein kinase via activation of p38 mitogen-activated protein kinase. J Biol Chem 2001; 276: 41029-41034.
18. Lemieux K, Konrad D, Klip A, Marette A. The AMP-activated protein kinase activator AlCAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases á and â in skeletal muscle. FASEB J 2003; 17: 1658-1665.
19. Hardie DG, Carling D, Carlson M. The AMP-activated/SNF1 protein kinase subfamily: Metabolic sensors of the eukaryotic cell. Annu Rev Biochem 1998; 67: 821-855.
20. Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA. Dealing with energy demand: The AMP-activated protein kinase. Trends Biochem Sci 1999; 24: 22-25.
21. Liang Y, Chen X, Osborne M, DeCarlo SO, Jetton TL, Demarest K. Topiramate ameliorates hyperglycaemia and improves glucose-stimulated insulin release in ZDF rats and db/db mice. Diabetes Obes Metab 2005; 4: 360-369.
22. McElroy SL, Arnold LM, Shapira NA, Keck PE, Rosenthal NR, Karim MR et al. Topiramate in the treatment of binge eating disorder associated with obesity: A randomized, placebo-controlled trial. Am J Psychiatry 2003; 160: 255-261.
23. Astrup A, Toubro S. Topiramate: A new potential pharmacological treatment for obesity. Obes Res 2004; 12(Suppl): 167S-173S.
24. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathgenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 318-368.
25. Shulman GI, Rothman DL, Jue T, Stein P, DeFronzo RA, Shulman RG. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1990; 322: 223-228.
26. Czech MP, Corvera S. Signaling mechanisms that regulate glucose transport. J Biol Chem 1999; 274: 1865-1868.
27. Cortright RN, Dohm GL. Mechanisms by which insulin and muscle contraction stimulate glucose transport. Can J Appl Physiol 1997; 22: 519-530.
28. Brozinick Jr JT, Bimbaum MJ. Insulin, but not contraction, activates Akt/ PKB in isolated rat skeletal muscle. J Biol Chem 1998; 273: 14679-14682.
29. Hayashi T, Hirshman MF, Kurth EJ, Winder WW, Goodyear LJ. Evidence for 5′ AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 1998; 47: 1369-1373.
30. Musi N, Hayashi T, Fujii N, Hirshman MF, Witters LA, Goodyear LJ. AMP-activated protein kinase activity and glucose uptake in rat skeletal muscle. Am J Physiol Endocrinol Metab 2001; 280: E677-E684.
31. Wilkes JJ, Nguyen MT, Bandyopadhyay GK, Nelson E, Olefsky JM. Topiramate treatment causes skeletal muscle insulin sensitization and increased Acrp30 secretion in High-Fa - Fed Male Wistar rats. Am J physiol Endocrinol Metab 2005; 289: E1015-E1022.
32. Eichhorn J, Kayali AG, Austin DA, Webster NJ. Insulin activates phospholipase C-gamma1 via a PI-3 kinase dependent mechanism in 3T3-L1 adipocytes. Biochem Biophy Res Commun 2001; 282: 615-620.
33. Kim MS, Lee J, Ha J, Kim SS, Kong Y, Cho YH et al. ATP stimulates glucose transport through activation of P2 purinergic receptors in C(2)C(12) skeletal muscle cells. Arch Biochem Biophys 2002; 401: 205-214.
34. Lee M, Hwang JT, Lee HJ, Jung SN, Kang I, Chi SG et al AMP-activated protein kinase activity is critical for hypoxia-inducible factor-1 transcriptional activity and its target gene expression under hypoxic conditions in DU145 cells. J Biol Chem 2003; 278: 39653-39661.